NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $19.89.

A number of analysts recently weighed in on the stock. Benchmark reiterated a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a research report on Tuesday, September 24th. Stephens reissued an “overweight” rating and set a $19.00 target price on shares of NeoGenomics in a research note on Tuesday, July 30th. Finally, Needham & Company LLC reissued a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research note on Wednesday, September 25th.

Hedge Funds Weigh In On NeoGenomics

Several hedge funds have recently made changes to their positions in the business. Arizona State Retirement System grew its stake in shares of NeoGenomics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company’s stock worth $496,000 after acquiring an additional 708 shares in the last quarter. Crossmark Global Holdings Inc. grew its stake in shares of NeoGenomics by 2.9% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 29,494 shares of the medical research company’s stock worth $409,000 after acquiring an additional 842 shares in the last quarter. Fernwood Investment Management LLC grew its stake in shares of NeoGenomics by 1.0% during the 3rd quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock worth $1,320,000 after acquiring an additional 900 shares in the last quarter. Blue Trust Inc. grew its stake in shares of NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after acquiring an additional 987 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its stake in shares of NeoGenomics by 3.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 32,505 shares of the medical research company’s stock valued at $451,000 after buying an additional 1,030 shares in the last quarter. 98.50% of the stock is owned by institutional investors.

NeoGenomics Stock Performance

Shares of NASDAQ:NEO opened at $14.14 on Tuesday. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -22.81 and a beta of 1.19. The firm’s 50 day simple moving average is $14.75 and its 200 day simple moving average is $14.71. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93. NeoGenomics has a fifty-two week low of $12.77 and a fifty-two week high of $21.22.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.